Zusammenfassung
β-Blocker wurden bereits in den 60er Jahren in die klinische Praxis eingeführt. Seitdem ist überzeugend demonstriert worden, daß einige β-Blocker die kardiovaskuläre Morbidität und Mortalität in Langzeitstudien bei Hypertonic [22] und zur Post-Myokardinfarkt-Prophylaxe [5] reduzieren. Es sind mehrere vermutliche Eigenschaften dieser Wirkstoffe mitgeteilt worden, die auf eine mögliche kardioprotektive Aktivität hinweisen:
-
Mechanismen
-
Verbesserung des Ungleichgewichts zwischen Koronardurchfluß und myokardialem Bedarf,
-
antiarrhythmische Wirkungen,
-
Schutz ischämischer Gewebe,
-
Reduzierung der Atheromentwicklung;
-
-
Wirkungen auf Daten beim Tier
-
koronare Durchflußmuster,
-
Infarktgröße,
-
Stoffwechselfunktionen,
-
Arrhythmien;
-
-
Klinisch
-
primäre Prävention,
-
akute Post-MI-Verabreichung,
-
chronische Post-MI-Verabreichung.
-
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abrahamsson B, Lucker P, Olofsson B, Regårdh C-G, Sandberg A, Wieselgren I, Bergstrand R (1990) The relationship between metoprolol plasma concentration and β1-blockade in healthy subjects: A study on conventional metoprolol and metoprolol CR/Zok formulations. J Clin Pharmacol 30: S46–S54.
Akhlaghi S, Maxwill SRJ, Kendall MJ, Hughes B, Greenhaff P (1993) A comparison of the β1-selectivity of conventional metoprolol and metoprolol CR during exercise in healthy volunteers. J Clin Pharm Ther 18: 259–266.
Benfield P, Clisold SP, Brogden RN (1986) Metoprolol: An update review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension, ischemic heart disease and related cardiovascular disorders. Drugs 31: 376–429.
Briant RH, Dorrington RE, Ferry DG, Paxton UW (1983) Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. Eur J Clin Pharmacol 25: 353–356.
Hjalmarson Å, Olsson G (1991) Myocardial infarction: Effects of β-blockade. Circulation 84 (suppl VI): VI101-VI107.
Johnsson G, Regårdh C-G, Sölvell L (1975) Combined pharmacokinetic and pharmacodynamic studies in man of the adrenergic β1-receptor antagonist metoprolol. Acta Pharmacol Toxicol 36 (suppl 5): 31–44.
Jordö L, Attman PO, Aurell M, Johansson L, Johnsson G, Regårdh C-G (1980) Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet 5: 169–180.
Kendall MJ (1981) Are selective β-adrenoceptor blocking drugs an advantage? J R Coll Physicians Lond 15: 33–39.
Kendall MJ, Akhlaghi S, Hughes B, Lewis H 1990) Is metoprolol CR/Zok more selective than conventional metoprolol and atenolol? J Clin Pharmacol 30: S98–S102.
Larsson M, Landahl S, Lundborg P, Regårdh C-G (1984) Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment. Eur J Clin Pharmacol 27: 217–222
Löfdahl CG, Svedmyr N (1981) Cardioselectivity of atenolol and metoprolol. A study in asthmatic patients. Eur J Respir Dis 62: 396–404
Löfdahl CG, Dahlöf C, Westergren G, Olofsson B, Svedmyr N (1988) Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline. Eur J Clin Pharmacol 33 (suppl): S25–S32.
Lucker P, Moore G, Wieselgren I, Olofsson B, Bergstrand R (1990) Pharmacokinetic and phar-macodynamic comparison of metoprolol CR/Zok once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 30: S17–S27.
Minneman KL, Hedberg A, Molinoff PB (1979) Comparison of β-adrenoceptor subtypes in mammalian tissue. J Pharm Exp Ther 211: 502–508.
Norwegian Multicenter Study Group (1981) Timolol-induced eduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807.
Omvik P, Leer J, Istad H, Westergren G (1994) Equal efficacy and improved tolerability with 50 mg controlled-release metoprolol compared with 100 mg conventional metoprolol in hyper-tensive patients. Am J Ther 1: 65–73.
Regårdh C-G (1982) Pharmacokinetic aspects of some β-blocking drugs. Acta Med Scand 665 (suppl): 49–60.
Regårdh C-G, Borg KO, Johansson R, Johnsson G, Palmer L (1974) Pharmacokinetic studies on the selective β1-receptor antagonist metoprolol in man. J. Pharmacokinet Biopharm 2: 347–364.
Sandberg A, Abrahamsson B, Regårdh C-G, Wieselgren I, Bergstrand R (1990) Pharmaco-kinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/Zok: A review article. J Clin Pharmacol 30: S2–S16.
Smith SR, Kendall MJ, Worthington DJ, Holder R (1983) Can the biochemical responses to a β2-adrenoceptor stimulant be used to assess the selectivity of β-adrenoceptors? Br J Clin Pharmacol 16: 557–560.
Westergren G, Olofsson B, Palevlief K (1994) Effective once-daily treatment of hypertension with low-dose controlled release metoprolol. Curr Ther Res 55: 142–148.
Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G (1988) Primary pre-vention with metoprolol in patients with hypertension: Mortality results from the MAPHY study. JAMA 259: 1976–1982.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Olsson, G. (1997). Klinische Relevanz der Pharmakokinetik für die Pharmakodynamik von ß-Blockern. In: Dominiak, P., Hjalmarson, A., Kendall, M.J., Kübler, W., Olsson, G. (eds) Betablocker — im Mittelpunkt der Forschung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60716-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-60716-5_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64522-8
Online ISBN: 978-3-642-60716-5
eBook Packages: Springer Book Archive